Friday, November 18, 2022

Neuropharmacological Actions of Metformin in Stroke

With this and all this earlier metformin research, is it being used in your hospital?

If not, you don't have functioning stroke doctors or hospital.

Earlier research has this line:The drug, which is cheaply available for just $0.16 a day, works by boosting the number of oxygen molecules released into a cell, which in turn seems to benefit the robustness and longevity of the body’s basic building blocks. (This would seem to be much easier and faster than HBOT. I'm requesting this at my next stroke, my doctor won't know what hit her when I tell her how to treat me.)

My list of 31 things I was going to demand after my next stroke. I guess metformin isn't in there.

 

 

Neuropharmacological Actions of Metformin in Stroke

Buy Article:

$68.00 + tax (Refund Policy)

Increasing epidemiologic evidence suggests that metformin, a well-established AMPK activator and the most favorable first-line anti-diabetic drug, reduces stroke incidence and severity. However, the mechanism for this remains unclear. Moreover, previous experimental studies have reported controversial results about the effects of metformin on stroke outcomes during the acute phase. However, recent studies have consistently suggested that AMPK-mediated microglia/macrophage polarization and angioneurogenesis may play essential roles in metformin-promoted, long-term functional recovery following stroke. The present review summarizes the neuropharmacological actions of metformin in experimental stroke with an emphasis on the recent findings that the cell-specific effects and duration of AMPK activation are critical to the effects of metformin on stroke outcomes.

Keywords: AMPK activation; anti-diabetic drug; metformin; neuropharmacological actions

Document Type: Research Article

Publication date: May 1, 2015

No comments:

Post a Comment